Literature DB >> 17040625

Current and emerging treatment approaches for tobacco dependence.

K Michael Cummings1, Martin Mahoney.   

Abstract

Nicotine in tobacco is the primary reason why most people find it hard to stop using tobacco. Nicotine creates dependence by activating the dopaminergic reward system in the brain. Physiologic withdrawal symptoms that occur when nicotine is no longer administered reinforce continued nicotine administration to avoid withdrawal. Extrapolating from this evidence has led to the development of tobacco dependence pharmacotherapy based upon the concept of replacing and/or blocking the effects of nicotine in the brain. The efficacy of nicotine replacement and blockade treatments in lessening symptoms of nicotine withdrawal and increasing quit rates has been consistently demonstrated in clinical trials. Despite the availability of efficacious medications to treat nicotine dependence, current therapies remain underutilized across the population. Health-care providers need to systematically encourage all tobacco users to quit and ensure that their tobacco-using patients use evidence-based treatments when they attempt to quit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040625     DOI: 10.1007/s11912-006-0077-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  47 in total

Review 1.  Individual differences in smoking reward from de-nicotinized cigarettes.

Authors:  L H Brauer; F M Behm; J D Lane; E C Westman; C Perkins; J E Rose
Journal:  Nicotine Tob Res       Date:  2001-05       Impact factor: 4.244

2.  Individual-level predictors of cessation behaviours among participants in the International Tobacco Control (ITC) Four Country Survey.

Authors:  A Hyland; R Borland; Q Li; H-H Yong; A McNeill; G T Fong; R J O'Connor; K M Cummings
Journal:  Tob Control       Date:  2006-06       Impact factor: 7.552

Review 3.  Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking.

Authors:  J E Rose; E D Levin
Journal:  Br J Addict       Date:  1991-05

Review 4.  The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.

Authors:  J Foulds
Journal:  Int J Clin Pract       Date:  2006-05       Impact factor: 2.503

Review 5.  Physician advice for smoking cessation.

Authors:  T Lancaster; L Stead
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

6.  Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

Authors:  Elaine C Johnstone; Patricia L Yudkin; Kate Hey; Sarah J Roberts; Sarah J Welch; Michael F Murphy; Siân E Griffiths; Robert T Walton
Journal:  Pharmacogenetics       Date:  2004-02

Review 7.  Review of bupropion for smoking cessation.

Authors:  Robyn Richmond; Nicholas Zwar
Journal:  Drug Alcohol Rev       Date:  2003-06

8.  Precessation treatment with nicotine skin patch facilitates smoking cessation.

Authors:  Jed E Rose; Frederique M Behm; Eric C Westman; Prity Kukovich
Journal:  Nicotine Tob Res       Date:  2006-02       Impact factor: 4.244

9.  High-dose nicotine patch therapy. Percentage of replacement and smoking cessation.

Authors:  L C Dale; R D Hurt; K P Offord; G M Lawson; I T Croghan; D R Schroeder
Journal:  JAMA       Date:  1995-11-01       Impact factor: 56.272

10.  Selling the "quit" brand to young adult smokers.

Authors:  K Michael Cummings; Gary A Giovino
Journal:  J Gen Intern Med       Date:  2004-05       Impact factor: 6.473

View more
  10 in total

Review 1.  Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders.

Authors:  Miranda L Fisher; Anu Loukola; Jaakko Kaprio; Jill R Turner
Journal:  Int Rev Neurobiol       Date:  2015-09-16       Impact factor: 3.230

Review 2.  The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence.

Authors:  Pretal P Muldoon; Aron H Lichtman; Loren H Parsons; M Imad Damaj
Journal:  Life Sci       Date:  2012-06-12       Impact factor: 5.037

Review 3.  New mechanisms and perspectives in nicotine withdrawal.

Authors:  K J Jackson; P P Muldoon; M De Biasi; M I Damaj
Journal:  Neuropharmacology       Date:  2014-11-26       Impact factor: 5.250

Review 4.  Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer.

Authors:  John P Finnigan; Andrew G Sikora
Journal:  Curr Oncol Rep       Date:  2014-03       Impact factor: 5.075

5.  Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence.

Authors:  Ami Cohen; George F Koob; Olivier George
Journal:  Neuropsychopharmacology       Date:  2012-05-02       Impact factor: 7.853

6.  Does the number of free nicotine patches given to smokers calling a quitline influence quit rates: results from a quasi-experimental study.

Authors:  K Michael Cummings; Brian V Fix; Paula Celestino; Andrew Hyland; Martin Mahoney; Deborah J Ossip; Ursula Bauer
Journal:  BMC Public Health       Date:  2010-04-07       Impact factor: 3.295

7.  Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs.

Authors:  K J Jackson; B R Martin; J P Changeux; M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2008-01-09       Impact factor: 4.030

8.  Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey.

Authors:  Brian V Fix; Andrew Hyland; Cheryl Rivard; Ann McNeill; Geoffrey T Fong; Ron Borland; David Hammond; K Michael Cummings
Journal:  Int J Environ Res Public Health       Date:  2011-01-20       Impact factor: 3.390

9.  The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.

Authors:  Aliou B Gueye; Yaroslaw Pryslawsky; Jose M Trigo; Nafsika Poulia; Foteini Delis; Katerina Antoniou; Michael Loureiro; Steve R Laviolette; Kiran Vemuri; Alexandros Makriyannis; Bernard Le Foll
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-30       Impact factor: 5.176

10.  Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking.

Authors:  Ami Cohen; Olivier George
Journal:  Front Psychiatry       Date:  2013-06-04       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.